Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rolapitant hydrochloride

Known as: Rolapitant Monohydrochloride Monohydrate, 1,7-Diazaspiro(4.5)decan-2-one, 8-(((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, Monohydrochloride, Monohydrate, (5S,8S)-, Rolapitant HCl 
The hydrochloride salt form of rolapitant, an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with… Expand
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

SCH 619734Varubi
rolapitantrolapitant 90 MG Oral Tablet [Varubi]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
SummaryRolapitant is a neurokinin-1 receptor antagonist that is approved in combination with other antiemetic agents in adults… Expand
Is this relevant?
2018
2018
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection.
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA… Expand
Is this relevant?
2018
2018
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride.
Prophylaxis or therapy with a combination of a neurokinin 1 (NK-1) receptor antagonist (RA), a 5-hydroxytryptamine- 3 (5-HT3) RA… Expand
Is this relevant?
Review
2017
Review
2017
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations
Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor… Expand
  • table 1
  • table 4
  • table 5
Is this relevant?
Review
2016
Review
2016
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) is a significant clinical issue which affects patients' quality of life as well… Expand
Is this relevant?
2016
2016
Prophylaxe bei hochemetogener Chemotherapie
Chemotherapiebedingte Übelkeit und Erbrechen (CINV) gefährden den Erfolg onkologischer Therapien. Rolapitant ist ein neuartiger… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE